生物相似药单株抗体市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按产品、按应用、地区、竞争细分。

2022年，全球生物相似药单株抗体（mAb）市值为52.2亿美元，预计在预测期内将大幅成长，预计到2028年复合年增长率为11.87%，预计到2028年将达到101.9亿美元。抗体（mAb）市场已成为生物製药行业中一个充满活力和变革的领域。生物相似药通常被称为生物药物的「仿製药」版本，因其在保持可比较的安全性和有效性的同时为昂贵的生物製剂提供具有成本效益的替代品的潜力而受到广泛关注。近年来，单株抗体生物相似药取得了显着的进步，重塑了製药格局，并为改善患者的可及性和医疗保健的可负担性打开了大门。单株抗体是一类生物药物，旨在针对体内特定的蛋白质、细胞或组织。事实证明，它们在治疗多种疾病方面非常有效，包括癌症、自体免疫疾病和发炎。然而，单株抗体的复杂性和复杂的製造过程导致了高昂的开发成本以及随后增加的治疗费用。生物相似药 mAb 本质上与已批准的参考 mAb 高度相似，采用重组 DNA 技术开发并在活细胞中製造。虽然由于生物製剂固有的变异性，它们可能与参考产品不同，但它们的设计在安全性、有效性和品质方面尽可能接近。主要驱动因素之一是全球医疗保健系统内迫切需要控製成本。生物相似药单株抗体具有显着减少医疗保健支出的潜力，因为与参考产品相比，它们通常以较低的价格进入市场，从而增强了市场的预期成长。

主要市场驱动因素

癌症和自体免疫疾病的增加推动了生物相似药单株抗体市场

市场概况
预测期	2024-2028
2022 年市场规模	52.2亿美元
2028 年市场规模	101.9亿美元
2023-2028 年复合年增长率	11.87%
成长最快的细分市场	肿瘤学
最大的市场	亚太地区

医疗保健领域见证了癌症和自体免疫疾病的盛行率大幅上升，这些复杂且具挑战性的医疗状况影响着全世界数百万人。随着这些疾病的发生率持续上升，对有效且负担得起的治疗方法的需求导致了生物相似药单株抗体（mAb）市场的出现和扩张。这个快速发展的细分市场在满足患者的治疗需求方面发挥关键作用，同时为医疗保健系统提供潜在的成本节约。癌症和自体免疫疾病代表了两种不同的医学挑战，两者的特征都是涉及免疫系统的复杂机制。癌症是一组以不受控制的细胞生长为特征的疾病，也是全球主要死亡原因之一。另一方面，自体免疫疾病是由错误的免疫反应引起的，即人体的免疫系统攻击自身的健康组织，导致慢性发炎和组织损伤。在过去的几十年里，由于人口老化、环境暴露、生活方式的改变和遗传倾向的推动，癌症和自体免疫疾病的发生率一直在稳步上升。因此，迫切需要创新且有效的疗法来治疗这些疾病并改善患者的生活品质。由于对癌症和自体免疫疾病更实惠的治疗方案的需求不断增加，生物相似药单株抗体市场迅速成长。美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构已製定生物相似药审批指南和途径，确保对其安全性和有效性进行严格评估。

不断增加的监管支持推动生物相似药单株抗体市场

为了解决对生物相似药单株抗体的安全性、有效性和品质的担忧，世界各地的监管机构制定了全面的指南和框架。这些指南概述了生物相似药产品在批准进入市场之前必须经过的严格的科学和临床评估流程。目标是确保患者和医疗保健专业人员可以相信生物相似药与其参考产品的等效性。例如，欧洲药品管理局 (EMA) 和美国食品药物管理局 (FDA) 都发布了针对生物相似药单株抗体的指南。这些指南强调广泛的比较分析研究，包括物理化学和功能表征，以及非临床和临床研究，以证明与参考产品的等效性。随着更多原厂单株抗体专利到期，生物相似药替代品的市场已经成熟。这为製造商进入市场并以有竞争力的价格提供替代品创造了机会。 EMA 和 FDA 等机构制定的严格监管途径和指南增强了医疗保健专业人员和患者对生物相似药单株抗体安全性和有效性的信心。

主要市场挑战

製造复杂性

单株抗体生物相似药的製造过程非常复杂，并且涉及活细胞，这可能会导致产品的变异性。保持与参考产品一致的品质和可比性是一项重大挑战。

临床试验和数据要求

产生证明生物相似药及其参考单株抗体之间安全性和有效性相似性的临床试验资料对于监管部门的批准至关重要。设计这些试验并确保患者招募可能非常复杂且耗费资源。

市场竞争

随着越来越多的公司进入单株抗体生物相似药市场，竞争加剧。定价策略、市场进入和差异化成为成功的关键因素。

主要市场趋势

技术进步

近年来，在生物技术和创新研究方法的显着进步的推动下，製药业经历了巨大的转变。在这些重大突破中，生物相似药单株抗体 (mAb) 已成为塑造医学格局的强大力量。这些尖端治疗药物正在彻底改变从癌症到自体免疫疾病等各种疾病的治疗。单株抗体生物相似药市场的快速成长与技术和创新的不断进步错综复杂地交织在一起。科技的进步使人们能够更深入地了解疾病机制和患者变异性。这为精准医学的概念铺平了道路，即根据患者的基因组成、疾病特征和对治疗的反应，为个别患者量身定制治疗方法。生物相似药单株抗体在这方面具有巨大的前景，因为它们可以被开发为更精确地针对特定疾病途径。这种方法不仅可以提高治疗效果，还可以最大限度地减少副作用，从而提高患者的生活品质。生物相似药单株抗体市场成长的关键驱动力之一是生物加工和製造技术的不断发展。细胞培养技术、纯化製程和生物反应器设计方面的创新使製造商能够生产具有更高纯度和产量的生物相似药单株抗体。这不仅确保了最终产品的安全性，而且还降低了生产成本，使这些疗法对于患者和医疗保健系统来说更加经济可行。生物相似药单株抗体与其参考产品的准确表征和比较对于确保其安全性和有效性至关重要。质谱、核磁共振和高效液相层析等分析技术的进步使得全面评估生物相似药和参考单株抗体之间的结构和功能相似性成为可能。这种详细程度对于监管部门的批准以及获得医生和患者对产品的信任至关重要。

细分市场洞察

产品洞察

2022 年，英夫利西单抗领域主导了生物相似药单株抗体市场，预计未来几年将继续扩大。英夫利西单抗是一种嵌合单株抗体，靶向併中和肿瘤坏死因子-α（TNF-α），这是一种参与发炎反应的细胞激素。英夫利西单抗最初以 Remicade (R) 品牌开发和销售，已成为治疗类风湿关节炎、克隆氏症、牛皮癣和僵直性脊椎炎自体免疫疾病的游戏规则改变者。

应用洞察

2022 年，肿瘤学领域主导了生物相似药单株抗体市场，预计未来几年将继续扩大。全球癌症负担一直在稳步增加，推动了对有效且负担得起的治疗方案的需求。生物相似药单株抗体以更低的成本提供与其原厂产品相当的功效和安全性，从而提供了一个有前景的解决方案。随着癌症发生率持续飙升，对肿瘤特异性单株抗体生物相似药的需求势将不断增加，使肿瘤学成为该市场的驱动力。

区域洞察

亚太地区拥有多元化的经济体，每个经济体都有其独特的医疗保健挑战。随着慢性病和复杂医疗状况负担的增加，对有效且负担得起的治疗方案的需求也在增长。生物相似药单株抗体提供了一种可行的解决方案，使许多患者能够获得以前在经济上无法承受的先进疗法。由于注重成本效益，亚洲医疗保健系统越来越多地转向生物相似药，以缩小两者之间的差距

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球生物相似药单株抗体市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产物（英夫利西单抗、利妥昔单抗、阿昔单抗、曲妥珠单抗、阿达木单抗、贝伐单抗等）
  • 按应用（肿瘤学、慢性病和自体免疫疾病、其他）
  • 按地区
  • 按公司划分（前 5 名市场参与者的股份）
• 市场地图
  • 按产品分类
  • 按应用
  • 按地区

第 6 章：北美生物相似药单株抗体市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 按应用
  • 按国家/地区

第 7 章：欧洲生物相似药单株抗体市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 按应用
  • 按国家/地区

第 8 章：亚太地区生物相似药单株抗体市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 按应用
  • 按国家/地区

第 9 章：南美洲生物相似药单株抗体市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按应用
  • 按国家/地区

第 10 章：中东和非洲生物相似药单株抗体市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 按应用
  • 按国家/地区

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第13章：竞争格局

• 雅培
• 辉瑞公司
• 诺华公司
• 艾伯维公司
• 科赫勒斯生物科学公司
• 百康有限公司
• 艾尔建公司。
• 雅阁医疗有限公司。
• 安进公司
• 雷迪博士的实验室

第 14 章：策略建议

第 15 章：关于我们与免责声明

The Global biosimilar monoclonal antibodies (mAbs) market, valued at USD 5.22 Billion in 2022, is poised for substantial growth in the forecast period, with a projected CAGR of 11.87% through 2028 and expected to reach USD 10.19 Billion in 2028. The biosimilar monoclonal antibodies (mAbs) market has emerged as a dynamic and transformative sector within the biopharmaceutical industry. Biosimilars, often referred to as "generic" versions of biologic drugs, have gained significant attention for their potential to provide cost-effective alternatives to expensive biologics while maintaining comparable safety and efficacy profiles. In recent years, biosimilar mAbs have made remarkable strides, reshaping the pharmaceutical landscape and opening doors to improved patient access and healthcare affordability. Monoclonal antibodies are a class of biologic drugs designed to target specific proteins, cells, or tissues within the body. They have proven highly effective in treating a wide range of diseases, including cancer, autoimmune disorders, and inflammatory conditions. However, the complex nature of mAbs and the intricate manufacturing processes involved have led to high development costs and subsequently elevated treatment expenses. Biosimilar mAbs, essentially highly similar versions of approved reference mAbs, are developed using recombinant DNA technology and manufactured in living cells. While they may not be identical to the reference product due to inherent variability in biologics, they are designed to be as close as possible in terms of safety, efficacy, and quality. One of the primary drivers is the urgent need for cost containment within healthcare systems worldwide. Biosimilar mAbs offer the potential to significantly reduce healthcare expenditure, as they typically enter the market at a lower price point compared to their reference counterparts, thus augmenting the projected growth of the market.

Key Market Drivers

Rising Cancer and Autoimmune Disorders Driving the Biosimilar Monoclonal Antibodies Market

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 5.22 Billion
Market Size 2028	USD 10.19 Billion
CAGR 2023-2028	11.87%
Fastest Growing Segment	Oncology
Largest Market	Asia Pacific

The healthcare landscape has witnessed a significant surge in the prevalence of cancer and autoimmune disorders, complex and challenging medical conditions affecting millions of individuals worldwide. As the incidence of these conditions continues to rise, the demand for effective and affordable treatments has led to the emergence and expansion of the biosimilar monoclonal antibodies (mAbs) market. This rapidly evolving market segment is playing a pivotal role in addressing the therapeutic needs of patients while offering potential cost savings for healthcare systems. Cancer and autoimmune disorders represent two distinct medical challenges, both characterized by complex mechanisms involving the immune system. Cancer, a group of diseases characterized by uncontrolled cell growth, is one of the leading global causes of death. Autoimmune disorders, on the other hand, result from a misdirected immune response where the body's immune system attacks its own healthy tissues, leading to chronic inflammation and tissue damage. The incidence of both cancer and autoimmune disorders has been steadily increasing over the past few decades, driven by aging populations, environmental exposures, lifestyle changes, and genetic predisposition. Consequently, there's an urgent need for innovative and effective therapies to treat these conditions and improve patients' quality of life. The biosimilar monoclonal antibodies market has rapidly grown due to the increasing demand for more affordable treatment options for cancer and autoimmune disorders. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines and pathways for biosimilar approval, ensuring rigorous evaluation of their safety and efficacy.

Rising Regulatory Support Driving the Biosimilar Monoclonal Antibodies Market

To address concerns about the safety, efficacy, and quality of biosimilar monoclonal antibodies, regulatory agencies worldwide have developed comprehensive guidelines and frameworks. These guidelines outline the rigorous scientific and clinical evaluation processes biosimilar products must undergo before approval for market entry. The goal is to ensure patients and healthcare professionals can trust the equivalence of biosimilars to their reference products. For example, both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have released guidelines addressing biosimilar monoclonal antibodies. These guidelines emphasize extensive comparative analytical studies, including physicochemical and functional characterization, as well as non-clinical and clinical studies to demonstrate equivalence to the reference product. As more originator monoclonal antibody patents expire, the market is ripe for biosimilar alternatives. This creates opportunities for manufacturers to enter the market and offer alternatives at competitive prices. The rigorous regulatory pathways and guidelines set by agencies like the EMA and FDA have instilled confidence in healthcare professionals and patients regarding the safety and efficacy of biosimilar monoclonal antibodies.

Key Market Challenges

Manufacturing Complexity

The manufacturing process for biosimilar mAbs is intricate and involves living cells, which can result in product variability. Maintaining consistent quality and comparability to the reference product is a significant challenge.

Clinical Trials and Data Requirements

Generating clinical trial data demonstrating similarity in safety and efficacy between a biosimilar and its reference mAb is essential for regulatory approval. Designing these trials and ensuring patient recruitment can be complex and resource-intensive.

Market Competition

As more companies enter the biosimilar mAbs market, competition intensifies. Pricing strategies, market access, and differentiation become critical factors for success.

Key Market Trends

Technological Advancements

The pharmaceutical industry has experienced a seismic shift in recent years, driven by remarkable advancements in biotechnology and innovative research methodologies. Among the significant breakthroughs, biosimilar monoclonal antibodies (mAbs) have emerged as a potent force shaping the medical landscape. These cutting-edge therapeutic agents are revolutionizing the treatment of various diseases, ranging from cancer to autoimmune disorders. The rapid growth of the biosimilar mAbs market is intricately intertwined with the continual progress in technology and innovation. Advancements in technology have enabled a deeper understanding of disease mechanisms and patient variability. This has paved the way for the concept of precision medicine, where treatments are tailored to individual patients based on their genetic makeup, disease characteristics, and response to therapy. Biosimilar mAbs hold immense promise in this regard, as they can be developed to target specific disease pathways with greater precision. This approach not only enhances therapeutic outcomes but also minimizes side effects, thereby improving patient quality of life. One of the key drivers behind the biosimilar mAbs market's growth is the continual evolution of bioprocessing and manufacturing technologies. Innovations in cell culture techniques, purification processes, and bioreactor designs have enabled manufacturers to produce biosimilar mAbs with higher purity and yield. This not only ensures the safety of the end product but also reduces production costs, making these therapies more economically viable for patients and healthcare systems. Accurate characterization and comparison of biosimilar mAbs with their reference products are critical to ensuring their safety and efficacy. Technological advancements in analytical techniques, such as mass spectrometry, nuclear magnetic resonance, and high-performance liquid chromatography, have made it possible to comprehensively assess the structural and functional similarities between biosimilars and reference mAbs. This level of detail is essential for regulatory approval and gaining physicians' and patients' trust in the product.

Segmental Insights

Product Insights

In 2022, the Infliximab segment dominated the Biosimilar Monoclonal Antibodies market and is predicted to continue expanding in the coming years. Infliximab is a chimeric monoclonal antibody that targets and neutralizes tumor necrosis factor-alpha (TNF-α), a cytokine involved in the inflammatory response. Originally developed and marketed under the brand name Remicade®, infliximab has been a game-changer in treating autoimmune diseases like rheumatoid arthritis, Crohn's disease, psoriasis, and ankylosing spondylitis.

Application Insights

In 2022, the Oncology segment dominated the Biosimilar Monoclonal Antibodies market and is predicted to continue expanding in the coming years. The global burden of cancer has been steadily increasing, driving the demand for effective and affordable treatment options. Biosimilar mAbs offer a promising solution by providing comparable efficacy and safety to their originator counterparts at a lower cost. As cancer incidence continues to surge, the demand for oncology-specific biosimilar mAbs is poised to escalate, making oncology a driving force in this market.

Regional Insights

The Asia-Pacific region hosts a diverse range of economies, each with its unique healthcare challenges. As the burden of chronic diseases and complex medical conditions increases, the demand for effective and affordable treatment options has grown. Biosimilar monoclonal antibodies offer a viable solution, providing access to advanced therapies that were previously financially out of reach for many patients. With a focus on cost-effectiveness, Asian healthcare systems are increasingly turning to biosimilars to bridge the gap between

Key Market Players

• Abbott
• Pfizer
• Novartis AG
• AbbVie, Inc.
• Coherus BioSciences
• Biocon Limited
• Allergan plc.
• Accord Healthcare limited.
• Amgen inc.
• Dr. Reddy's Laboratory

Report Scope:

• In this report, the Global Biosimilar Monoclonal Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilar Monoclonal Antibodies Market, By Product:

• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab
• Other

Biosimilar Monoclonal Antibodies Market, By Application:

• Oncology
• Chronic & Autoimmune Diseases
• Others

Biosimilar Monoclonal Antibodies Market, By Region:

• North America
• Asia-Pacific
• Europe
• Middle East & Africa
• South America

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Biosimilar Monoclonal Antibodies Market.

Available Customizations:

• Global Biosimilar Monoclonal Antibodies Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biosimilar Monoclonal Antibodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab and Other)
  • 5.2.2. By Application (Oncology, Chronic & Autoimmune Diseases, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (Shares of Top 5 Market Players)
• 5.3. Market Map
  • 5.3.1. By Product
  • 5.3.2. By Application
  • 5.3.3. By Region

6. North America Biosimilar Monoclonal Antibodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
    • 6.2.3.1. United States Biosimilar Monoclonal Antibodies Market Outlook
      • 6.2.3.1.1. Market Size & Forecast
      • 6.2.3.1.1.1. By Value
      • 6.2.3.1.2. Market Share & Forecast
      • 6.2.3.1.2.1. By Product
      • 6.2.3.1.2.2. By Application
    • 6.2.3.2. Canada Biosimilar Monoclonal Antibodies Market Outlook
      • 6.2.3.2.1. Market Size & Forecast
      • 6.2.3.2.1.1. By Value
      • 6.2.3.2.2. Market Share & Forecast
      • 6.2.3.2.2.1. By Product
      • 6.2.3.2.2.2. By Application
    • 6.2.3.3. Mexico Biosimilar Monoclonal Antibodies Market Outlook
      • 6.2.3.3.1. Market Size & Forecast
      • 6.2.3.3.1.1. By Value
      • 6.2.3.3.2. Market Share & Forecast
      • 6.2.3.3.2.1. By Test
      • 6.2.3.3.2.2. By Application

7. Europe Biosimilar Monoclonal Antibodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2.
  • 7.2.3. By Application
  • 7.2.4. By Country
    • 7.2.4.1. France Biosimilar Monoclonal Antibodies Market Outlook
      • 7.2.4.1.1. Market Size & Forecast
      • 7.2.4.1.1.1. By Value
      • 7.2.4.1.2. Market Share & Forecast
      • 7.2.4.1.2.1. By Product
      • 7.2.4.1.2.2. By Application
    • 7.2.4.2. Germany Biosimilar Monoclonal Antibodies Market Outlook
      • 7.2.4.2.1. Market Size & Forecast
      • 7.2.4.2.1.1. By Value
      • 7.2.4.2.2. Market Share & Forecast
      • 7.2.4.2.2.1. By Product
      • 7.2.4.2.2.2. By Application
    • 7.2.4.3. United Kingdom Biosimilar Monoclonal Antibodies Market Outlook
      • 7.2.4.3.1. Market Size & Forecast
      • 7.2.4.3.1.1. By Value
      • 7.2.4.3.2. Market Share & Forecast
      • 7.2.4.3.2.1. By Product
      • 7.2.4.3.2.2. By Application
    • 7.2.4.4. Italy Biosimilar Monoclonal Antibodies Market Outlook
      • 7.2.4.4.1. Market Size & Forecast
      • 7.2.4.4.1.1. By Value
      • 7.2.4.4.2. Market Share & Forecast
      • 7.2.4.4.2.1. By Product
      • 7.2.4.4.2.2. By Application
    • 7.2.4.5. Spain Biosimilar Monoclonal Antibodies Market Outlook
      • 7.2.4.5.1. Market Size & Forecast
      • 7.2.4.5.1.1. By Value
      • 7.2.4.5.2. Market Share & Forecast
      • 7.2.4.5.2.1. By Product
      • 7.2.4.5.2.2. By Application

8. Asia Pacific Biosimilar Monoclonal Antibodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
    • 8.2.3.1. China Biosimilar Monoclonal Antibodies Market Outlook
      • 8.2.3.1.1. Market Size & Forecast
      • 8.2.3.1.1.1. By Value
      • 8.2.3.1.2. Market Share & Forecast
      • 8.2.3.1.2.1. By Product
      • 8.2.3.1.2.2. By Application
    • 8.2.3.2. India Biosimilar Monoclonal Antibodies Market Outlook
      • 8.2.3.2.1. Market Size & Forecast
      • 8.2.3.2.1.1. By Value
      • 8.2.3.2.2. Market Share & Forecast
      • 8.2.3.2.2.1. By Product
      • 8.2.3.2.2.2. By Application
    • 8.2.3.3. South Korea Biosimilar Monoclonal Antibodies Market Outlook
      • 8.2.3.3.1. Market Size & Forecast
      • 8.2.3.3.1.1. By Value
      • 8.2.3.3.2. Market Share & Forecast
      • 8.2.3.3.2.1. By Product
      • 8.2.3.3.2.2. By Application
    • 8.2.3.4. Japan Biosimilar Monoclonal Antibodies Market Outlook
      • 8.2.3.4.1. Market Size & Forecast
      • 8.2.3.4.1.1. By Value
      • 8.2.3.4.2. Market Share & Forecast
      • 8.2.3.4.2.1. By Product
      • 8.2.3.4.2.2. By Application
    • 8.2.3.5. Australia Biosimilar Monoclonal Antibodies Market Outlook
      • 8.2.3.5.1. Market Size & Forecast
      • 8.2.3.5.1.1. By Value
      • 8.2.3.5.2. Market Share & Forecast
      • 8.2.3.5.2.1. By Product
      • 8.2.3.5.2.2. By Application

9. South America Biosimilar Monoclonal Antibodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2.
  • 9.2.3. By Application
  • 9.2.4. By Country
    • 9.2.4.1. Brazil Biosimilar Monoclonal Antibodies Market Outlook
      • 9.2.4.1.1. Market Size & Forecast
      • 9.2.4.1.1.1. By Value
      • 9.2.4.1.2. Market Share & Forecast
      • 9.2.4.1.2.1. By Product
      • 9.2.4.1.2.2. By Application
    • 9.2.4.2. Argentina Biosimilar Monoclonal Antibodies Market Outlook
      • 9.2.4.2.1. Market Size & Forecast
      • 9.2.4.2.1.1. By Value
      • 9.2.4.2.2. Market Share & Forecast
      • 9.2.4.2.2.1. By Product
      • 9.2.4.2.2.2. By Application
    • 9.2.4.3. Colombia Biosimilar Monoclonal Antibodies Market Outlook
      • 9.2.4.3.1. Market Size & Forecast
      • 9.2.4.3.1.1. By Value
      • 9.2.4.3.2. Market Share & Forecast
      • 9.2.4.3.2.1. By Product
      • 9.2.4.3.2.2. By Application

10. Middle East & Africa Biosimilar Monoclonal Antibodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
    • 10.2.3.1. South Africa Biosimilar Monoclonal Antibodies Market Outlook
      • 10.2.3.1.1. Market Size & Forecast
      • 10.2.3.1.1.1. By Value
      • 10.2.3.1.2. Market Share & Forecast
      • 10.2.3.1.2.1. By Product
      • 10.2.3.1.2.2. By Application
    • 10.2.3.2. Saudi Arabia Biosimilar Monoclonal Antibodies Market Outlook
      • 10.2.3.2.1. Market Size & Forecast
      • 10.2.3.2.1.1. By Value
      • 10.2.3.2.2. Market Share & Forecast
      • 10.2.3.2.2.1. By Product
      • 10.2.3.2.2.2. By Application
    • 10.2.3.3. UAE Biosimilar Monoclonal Antibodies Market Outlook
      • 10.2.3.3.1. Market Size & Forecast
      • 10.2.3.3.1.1. By Value
      • 10.2.3.3.2. Market Share & Forecast
      • 10.2.3.3.2.1. By Product
      • 10.2.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Abbott
• 13.2. Pfizer
• 13.3. Novartis AG
• 13.4. AbbVie, Inc.
• 13.5. Coherus BioSciences
• 13.6. Biocon Limited
• 13.7. Allergan plc.
• 13.8. Accord Healthcare limited.
• 13.9. Amgen inc.
• 13.10. Dr. Reddy's Laboratory

14. Strategic Recommendations

15. About us & Disclaimer